

Backing Cambridge: Life Sciences and Deep Tech with Cambridge Innovation Capital
Backing Cambridge: Life Sciences and Deep Tech with Cambridge Innovation Capital
CUVCPE and Trinity Enterprenership Society is delighted to welcome two investors from Cambridge Innovation Capital (CIC) for a fireside chat on backing life sciences and deep tech companies in Cambridge, and on moving from a PhD into venture capital.
About Emily - Life Sciences analyst Emily is an Analyst with CIC’s Life Sciences team. She holds a PhD in Pathology from the University of Cambridge, where she used multi-omics approaches to study cancers of the immune system. She also holds an MBiolSci in Biochemistry and Microbiology from the University of Sheffield, and completed her master’s research in AstraZeneca’s Oncology Bioscience team.
About Richard - Technology analyst Richard is an Associate specialising in technology investments. He joined CIC from Ab Initio Software, where he advised enterprise-level businesses on their data processing applications. He holds a PhD in Experimental Astrophysics and an MRes in Sensor Technologies from the University of Cambridge, and an MPhys from the University of Sheffield.
About CIC CIC is a leading Series A investor in the Cambridge ecosystem, born out of a unique relationship with the University of Cambridge. Its agreement with the University gives it privileged access to investment opportunities in life sciences and deep tech. It has £0.6bn of assets under management and has backed more than 45 companies. Its early-stage funds invest from seed through Series A, and its opportunity and growth funds provide scale-up capital to later-stage companies. The portfolio includes Cambridge GaN Devices, Pragmatic Semiconductor, Riverlane, Salience Labs and Microbiotica. CIC also builds companies through its Entrepreneur in Residence programme, which matches experienced entrepreneurs with Cambridge researchers, and through two accelerators, Start Codon for life sciences and Deeptech Labs for technology.
Join us to hear Emily and Richard on how CIC evaluates spinouts, what early-career investors actually do, and how to make the move from research into venture capital.